CCL5 and type 2 diabetes mellitus: Studies on patients with type 2 diabetes (T2D) and hypertriglyceridemia indicated that fenofibrate reduces the serum levels of the inflammatory marker RANTES, thus indicating its potential anti-inflammatory effects related to MASLD.